ClearPoint Neuro, Inc.

NasdaqCM:CLPT Stock Report

Market Cap: US$428.8m

ClearPoint Neuro Future Growth

Future criteria checks 2/6

ClearPoint Neuro is forecast to grow earnings and revenue by 9.8% and 29.8% per annum respectively while EPS is expected to grow by 12.3% per annum.

Key information

9.8%

Earnings growth rate

12.3%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate29.8%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Dec 2024

Recent future growth updates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

Earnings and Revenue Growth Forecasts

NasdaqCM:CLPT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202665N/AN/AN/A1
12/31/202539-16N/AN/A3
12/31/202432-18N/AN/A3
9/30/202430-18-9-9N/A
6/30/202428-18-10-9N/A
3/31/202426-21-13-12N/A
12/31/202324-22-15-14N/A
9/30/202322-22-17-16N/A
6/30/202322-21-19-18N/A
3/31/202321-18-19-18N/A
12/31/202221-16-17-16N/A
9/30/202220-16-18-17N/A
6/30/202219-16-17-16N/A
3/31/202217-16-15-15N/A
12/31/202116-14-13-13N/A
9/30/202116-12-12-12N/A
6/30/202115-9-10-10N/A
3/31/202114-7-8-8N/A
12/31/202013-7-8-8N/A
9/30/202012-7-6-6N/A
6/30/202012-6-6-5N/A
3/31/202012-6-5-5N/A
12/31/201911-6-3-3N/A
9/30/201910-5-3-3N/A
6/30/20199-5-3-3N/A
3/31/20198-6-3-3N/A
12/31/20187-6-5-5N/A
9/30/20187-7-6-6N/A
6/30/20187-7N/A-6N/A
3/31/20187-7N/A-7N/A
12/31/20177-7N/A-6N/A
9/30/20177-7N/A-5N/A
6/30/20177-8N/A-5N/A
3/31/20176-8N/A-6N/A
12/31/20166-8N/A-6N/A
9/30/20166-8N/A-6N/A
6/30/20165-5N/A-6N/A
3/31/20165-7N/A-7N/A
12/31/20155-8N/A-9N/A
9/30/20154-9N/A-9N/A
6/30/20153-13N/A-10N/A
3/31/20154-11N/A-9N/A
12/31/20144-5N/A-7N/A
9/30/20144-4N/A-7N/A
6/30/20144-4N/A-6N/A
3/31/20143-4N/A-7N/A
12/31/20134-7N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLPT's revenue (29.8% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: CLPT's revenue (29.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CLPT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ClearPoint Neuro, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Kyle BauserB. Riley Securities, Inc.
Sally YanchusBrookline Capital Markets